News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Corgenix Medical Corporation (CONX) and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)



12/14/2009 9:47:52 AM

DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation , a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine. BG Medicine is seeking regulatory clearance in the United States of the BGM Galectin-3 kit for clinical use in patients with heart failure.

"We are extremely pleased to extend our collaboration with BG Medicine to include the manufacturing of the BGM Galectin-3 kit," said Douglass Simpson, Corgenix President and Chief Executive Officer. "BG Medicine is bringing cutting edge technology and science to the cardiology market and we look forward to a long-term relationship."

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Corgenix Medical Corporation








Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES